AZN · story · 2 November – 3 November
AstraZeneca · 5 headlines from 5 outlets, from 2 November 2026 to 3 November 2026.
Pieces cover the lung cancer filings under EU and Japanese review for Orpathys with Tagrisso.
The story's tone is the average of its headlines' own scores. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone.
MyChesCo is the largest at 10.0, 1.7 times AllSci (5.8). AstraZeneca is the smallest at 1.7.
Source: MarketFrame news analysis
| outlet | Average tone |
|---|---|
| MyChesCo | 10.0 |
| AllSci | 5.8 |
| GenomeWeb | 5.8 |
| PharmaTimes | 5.8 |
| AstraZeneca | 1.7 |
| Outlet | Headlines | Average tone |
|---|---|---|
| MyChesCo | 1 | +10.0 |
| AllSci | 1 | +5.8 |
| GenomeWeb | 1 | +5.8 |
| PharmaTimes | 1 | +5.8 |
| AstraZeneca | 1 | +1.7 |
One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.
| Tone | What the article reported, and why it scored that way |
|---|---|
| +5.8 | Regulators in Europe and Japan accepting lung cancer combination for review. |
| +5.8 | Overseas regulators examining its lung cancer combination. |
| +5.8 | Lung cancer therapy filings progressing with regulators. |
| +1.7 | Company's own commentary on its lung cancer research approach. |
| Tone | What the article reported, and why it scored that way |
|---|---|
| +10.0 | Combination therapy shows improved patient survival in lung cancer. |
A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.